Tehran Darou
Pharmaceutical Company, was established in 1955 under the name of Mycin
Laboratory by Dr. Delavari, a graduate of Tehran University's Faculty of
Pharmacy, and Mr. Yaghoubian, a chemical merchant, in Tehran. As one of the
first pharmaceutical companies in Iran with Iranian founders and investors, it
held great significance in the industry.
In the 1960s,
the entry of American and European companies and investors into Iran's
pharmaceutical industry prompted Iranian companies, including Mycin Laboratory,
to contemplate development and industrialization. With this in mind, the
company's shareholders made the decision to construct a factory at its current
location on the 9th kilometer of Karaj Makhsous Road, spanning an area of 9681 square
meters.
In 1979, the
factory commenced operations, enabling the company to relocate and benefit from
advanced laboratories, warehouses, machines, and production lines for solids,
liquids, ointments, and creams. This pivotal move facilitated significant
success for the company.
In 1984, the
company's name was changed to Tehran Darou Pharmaceutical Company. Subsequent
to the country's economic growth, the company underwent renovations and
development, ensuring its sustained operations amidst changing times.
More recently,
Tehran Darou Pharmaceutical Company has made noteworthy strides, earning
various accolades and certificates, which include:
GMP
certificate for the food solids production line in 2018.
Receiving
the 7th national award for the quality of food, medicine, and health in Iran
for the years 2017-2018.
accreditation
certificate of control laboratories in 2022.
export
GMP certificate in 2023.
With almost 70
years of experience and a continuous growth trajectory, Tehran Daro
Pharmaceutical Company currently produces approximately 200 products across 14
pharmaceutical categories. Its products adhere to international standards and
meet the regulations set by the Food and Drug Organization. As a result, the
company has played a pivotal role in advancing healthcare and exports within
the country. It consistently strives to offer a diverse range of pharmaceutical
products and dietary supplements across various treatment groups, including
cardiovascular, antibiotics, painkillers, antidiabetic, gastrointestinal, and
central nervous system. This is made possible through the expertise of over 300
experienced professionals.
Moreover,
Tehran Darou Pharmaceutical Company produces nearly 2 billion units of tablets,
capsules, and soft gels annually, utilizing state-of-the-art machinery. A new
site is currently under construction, which is expected to enhance the quality
and efficiency of production lines. This will, in turn, facilitate significant
progress in the development of quality control and research laboratories.
In conclusion,
Tehran Darou Pharmaceutical Company's rich history, dedication to high-quality
production, adherence to international standards, and commitment to research
and development have solidified its position as a leading player in the pharmaceutical
industry.